Related Experiment Video

Updated: Jan 15, 2026

Isolation of Neonatal Extrahepatic Cholangiocytes
07:54

Isolation of Neonatal Extrahepatic Cholangiocytes

Published on: June 5, 2014

10.8K

Ursodeoxycholic acid for the treatment of cholestasis in newborn infants

Vikas Bolisetty1, Srinivas Bolisetty2, Jane Cracknell3

  • 1University of Newcastle / University of New England, Newcastle, Australia.

The Cochrane Database of Systematic Reviews
|October 14, 2025
PubMed

Insights

This review will examine ursodeoxycholic acid for treating newborn infant cholestasis. We aim to assess its benefits and potential harms in this vulnerable population.

Area of Science:

  • Neonatology
  • Pediatric Gastroenterology
  • Pharmacology

Background:

  • Cholestasis in newborn infants is a serious condition characterized by impaired bile flow.
  • Ursodeoxycholic acid is a bile acid used to treat certain liver conditions.

Purpose of the Study:

  • To evaluate the benefits and harms of ursodeoxycholic acid (UDCA) for treating cholestasis in newborn infants.

Main Methods:

  • This is a protocol for a Cochrane Review.
  • Systematic review methodology will be employed.
  • Data will be synthesized to assess efficacy and safety.

Main Results:

  • Results are pending completion of the systematic review.
  • The review will analyze existing evidence on UDCA's impact on cholestasis markers and infant health outcomes.
  • Potential adverse events associated with UDCA will be documented.

Conclusions:

  • Conclusions will be drawn based on the synthesized evidence regarding UDCA's role in neonatal cholestasis.
  • The findings will inform clinical practice and future research directions.
  • Evidence on the benefits and harms of UDCA in this population will be clarified.
Abstract

More Related Videos

Extrahepatic Bile Duct and Gall Bladder Dissection in Nine-Day-Old Mouse Neonates06:10

Extrahepatic Bile Duct and Gall Bladder Dissection in Nine-Day-Old Mouse Neonates

Published on: August 23, 2022

2.4K
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

54.4K

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
253
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
717
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
631
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.6K